Shanghai Bao Pharmaceuticals Co., Ltd. (2659)

Overview

Shanghai Bao Pharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical company that utilizes innovative synthetic biology technology to develop and manufacture a range of recombinant biologic drugs, enzymes, protein hormones, and antibodies. Established in 2019 and headquartered in Shanghai, China, the company is dedicated to advancing therapeutic solutions, focusing on areas such as immunology, infectious diseases, endocrinology, and oncology.

Shanghai Bao Pharmaceuticals operates GMP-compliant manufacturing facilities, assuring high-quality production processes for its products. The company is committed to addressing critical healthcare challenges, with a robust pipeline targeting conditions such as infertility, Guillain-Barré syndrome, renal transplant desensitization, burns, and neoplasms. Through its offerings, the company is poised to make significant contributions to bioprocessing and drug design platforms within the pharmaceutical industry.

Products and Services

• KJ017 - Recombinant Human Hyaluronidase: This product plays a crucial role in enhancing the efficacy of therapies by increasing the dispersion and absorption of co-administered drugs, particularly in the context of localized treatment.
• KJ103 - Recombinant IgG-Degrading Enzyme: Designed to reduce the levels of pathogenic IgG antibodies, KJ103 holds promise in addressing autoimmune disorders by targeting and degrading excessive IgG responses.
• SJ02 - Long-Acting Recombinant Human Follicle-Stimulating Hormone Fusion Protein: This product offers an advanced solution for treating infertility, mimicking the natural patterns of hormone release and promoting follicle development.
• BJ044 - Recombinant Ulinastatin: BJ044 is utilized for its protective effects against organ damage, particularly in cases of severe acute pancreatitis and other critical conditions.
• BJ007 - Subcutaneous Ceftriaxone Sodium: This formulation is aimed at treating bacterial infections, providing intravenous efficacy through subcutaneous delivery, which may enhance patient compliance.
• KJ101 - Recombinant Human Chymotrypsin: This enzyme is utilized in various medical contexts, particularly for its role in aiding digestion and managing inflammatory conditions.